[go: up one dir, main page]

IT1303249B1 - Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. - Google Patents

Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.

Info

Publication number
IT1303249B1
IT1303249B1 IT1998MI002280A ITMI982280A IT1303249B1 IT 1303249 B1 IT1303249 B1 IT 1303249B1 IT 1998MI002280 A IT1998MI002280 A IT 1998MI002280A IT MI982280 A ITMI982280 A IT MI982280A IT 1303249 B1 IT1303249 B1 IT 1303249B1
Authority
IT
Italy
Prior art keywords
sulphonamids
propionyl
aryl
contain
pharmaceutical preparations
Prior art date
Application number
IT1998MI002280A
Other languages
English (en)
Inventor
Riccardo Bertini
Cinzia Bizzarri
Vilma Sabbatini
Stefano Porzio
Gianfranco Caselli
Marcello Allegretti
Maria Candida Cesta
Carmelo A Gandolfi
Marco Mantovanini
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of ITMI982280A0 publication Critical patent/ITMI982280A0/it
Priority to IT1998MI002280A priority Critical patent/IT1303249B1/it
Priority to JP2000578281A priority patent/JP4194761B2/ja
Priority to CA002347752A priority patent/CA2347752C/en
Priority to SK538-2001A priority patent/SK286372B6/sk
Priority to AT99953824T priority patent/ATE230723T1/de
Priority to CNA2004100856352A priority patent/CN1615833A/zh
Priority to PT99953824T priority patent/PT1123276E/pt
Priority to EEP200100233A priority patent/EE04912B1/xx
Priority to US09/830,075 priority patent/US6887903B1/en
Priority to PCT/EP1999/007740 priority patent/WO2000024710A1/en
Priority to HU0103793A priority patent/HU225107B1/hu
Priority to EP99953824A priority patent/EP1123276B1/en
Priority to NZ511077A priority patent/NZ511077A/en
Priority to IL14249699A priority patent/IL142496A0/xx
Priority to DK99953824T priority patent/DK1123276T3/da
Priority to RU2001113733/04A priority patent/RU2255084C2/ru
Priority to CNB998124516A priority patent/CN100368394C/zh
Priority to HK02102780.8A priority patent/HK1041255B/zh
Priority to TR2001/01124T priority patent/TR200101124T2/xx
Priority to ES99953824T priority patent/ES2190264T3/es
Priority to CZ20011441A priority patent/CZ296434B6/cs
Priority to KR10-2001-7004865A priority patent/KR100484370B1/ko
Priority to DE69904852T priority patent/DE69904852T2/de
Priority to BRPI9914741-6 priority patent/BRPI9914741B8/pt
Priority to PL347947A priority patent/PL212210B1/pl
Priority to AU10375/00A priority patent/AU769850B2/en
Publication of ITMI982280A1 publication Critical patent/ITMI982280A1/it
Application granted granted Critical
Publication of IT1303249B1 publication Critical patent/IT1303249B1/it
Priority to NO20012000A priority patent/NO327537B1/no
Priority to NZ525084A priority patent/NZ525084A/en
Priority to US10/460,203 priority patent/US6881755B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
IT1998MI002280A 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. IT1303249B1 (it)

Priority Applications (29)

Application Number Priority Date Filing Date Title
IT1998MI002280A IT1303249B1 (it) 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
DK99953824T DK1123276T3 (da) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamider og farmaceutiske præparater indeholdende dem
RU2001113733/04A RU2255084C2 (ru) 1998-10-23 1999-10-14 N-(2-арилпропионил)сульфонамиды и содержащие их фармацевтические препараты
SK538-2001A SK286372B6 (sk) 1998-10-23 1999-10-14 N-2-Arylpropionylsulfónamidy, farmaceutické prostriedky s ich obsahom a ich použitie
AT99953824T ATE230723T1 (de) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)sulfonamide und sie enthaltende pharmazeutische zubereitungen
CNA2004100856352A CN1615833A (zh) 1998-10-23 1999-10-14 N－(2－芳基－丙酰基)－磺胺类化合物及其药物组合物
PT99953824T PT1123276E (pt) 1998-10-23 1999-10-14 N-(2-aril-propionil)-sulfonamidas e preparacoes farmaceuticas que as contem
EEP200100233A EE04912B1 (et) 1998-10-23 1999-10-14 N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina
US09/830,075 US6887903B1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
PCT/EP1999/007740 WO2000024710A1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
HU0103793A HU225107B1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
EP99953824A EP1123276B1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
NZ511077A NZ511077A (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
IL14249699A IL142496A0 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
JP2000578281A JP4194761B2 (ja) 1998-10-23 1999-10-14 Ｎ−（２−アリール−プロピオニル）−スルホンアミド類及びそれらを含む医薬製剤
CNB998124516A CN100368394C (zh) 1998-10-23 1999-10-14 N-(2-芳基-丙酰基)-磺胺类化合物及其药物组合物
ES99953824T ES2190264T3 (es) 1998-10-23 1999-10-14 N-(2-aril-propionil)sulfonamidas y preparaciones farmaceuticas que las contienen.
CA002347752A CA2347752C (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
TR2001/01124T TR200101124T2 (tr) 1998-10-23 1999-10-14 N-(2-aril-propiyonil)-sülfonamidler ve bunları içeren farmasötik preparasyonlar.
HK02102780.8A HK1041255B (zh) 1998-10-23 1999-10-14 N-(2-芳基-丙酰基)-磺胺类化合物及其药物组合物
CZ20011441A CZ296434B6 (cs) 1998-10-23 1999-10-14 N-(2-arylpropionyl)sulfonamidy a farmaceutický prostredek
KR10-2001-7004865A KR100484370B1 (ko) 1998-10-23 1999-10-14 Ｎ-(2-아릴-프로피오닐)-설폰아미드 및 이를 함유하는제약학적 조성물
DE69904852T DE69904852T2 (de) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)sulfonamide und sie enthaltende pharmazeutische zubereitungen
BRPI9914741-6 BRPI9914741B8 (pt) 1998-10-23 1999-10-14 n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
PL347947A PL212210B1 (pl) 1998-10-23 1999-10-14 N-(2-arylo-propionylo)sulfonamidy, ich zastosowanie i zawierające je kompozycje farmaceutyczne
AU10375/00A AU769850B2 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
NO20012000A NO327537B1 (no) 1998-10-23 2001-04-23 N-(2-aryl-propionyl)-sulfonamider, fremgangsmate for fremstilling derav og farmasoytiske prepareringer som inneholder dem
NZ525084A NZ525084A (en) 1998-10-23 2003-04-01 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
US10/460,203 US6881755B2 (en) 1998-10-23 2003-06-13 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002280A IT1303249B1 (it) 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.

Publications (3)

Publication Number Publication Date
ITMI982280A0 ITMI982280A0 (it) 1998-10-23
ITMI982280A1 ITMI982280A1 (it) 2000-04-23
IT1303249B1 true IT1303249B1 (it) 2000-11-06

Family

ID=11380926

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1998MI002280A IT1303249B1 (it) 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.

Country Status (26)

Country Link
US (2) US6887903B1 (it)
EP (1) EP1123276B1 (it)
JP (1) JP4194761B2 (it)
KR (1) KR100484370B1 (it)
CN (2) CN1615833A (it)
AT (1) ATE230723T1 (it)
AU (1) AU769850B2 (it)
BR (1) BRPI9914741B8 (it)
CA (1) CA2347752C (it)
CZ (1) CZ296434B6 (it)
DE (1) DE69904852T2 (it)
DK (1) DK1123276T3 (it)
EE (1) EE04912B1 (it)
ES (1) ES2190264T3 (it)
HK (1) HK1041255B (it)
HU (1) HU225107B1 (it)
IL (1) IL142496A0 (it)
IT (1) IT1303249B1 (it)
NO (1) NO327537B1 (it)
NZ (2) NZ511077A (it)
PL (1) PL212210B1 (it)
PT (1) PT1123276E (it)
RU (1) RU2255084C2 (it)
SK (1) SK286372B6 (it)
TR (1) TR200101124T2 (it)
WO (1) WO2000024710A1 (it)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318466B1 (it) * 2000-04-14 2003-08-25 Dompe Spa Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
AU2003289993B8 (en) * 2002-12-10 2008-05-08 Dompe' Farmaceutici S.P.A. Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
EP1457485A1 (en) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
WO2004111012A1 (ja) * 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
PT1776336E (pt) * 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
ES2279248T3 (es) * 2004-03-25 2007-08-16 Dompe' Pha.R.Ma S.P.A. Uso de n-(2-aril-propionil)-sulfonamidas para el tratamiento de lesiones de la medula espinal.
PT1856031E (pt) 2004-12-15 2009-05-14 Dompe Pha R Ma Spa Res & Mfg Derivados de ácidos 2-arilpropiónicos e composições farmacêuticas que os contenham
EP1844001B1 (en) * 2005-01-25 2009-06-10 DOMPE' pha.r.ma s.p.a. Metabolites of 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
ES2597843T3 (es) * 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
WO2010009212A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Niacin derivatives useful to treat metabolic syndromes
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN103172547B (zh) * 2011-12-20 2016-10-12 天津市国际生物医药联合研究院 磺酰胺衍生物的制备及其应用
CN103159674A (zh) * 2013-04-03 2013-06-19 苏州安诺生物医药技术有限公司 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途
US12268671B2 (en) * 2016-01-15 2025-04-08 Dompé Farmaceutici S.P.A. IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
JP7252125B2 (ja) 2016-10-03 2023-04-04 ザ チルドレンズ メディカル センター コーポレーション 糖尿病性腎症の予防および処置
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3409277A1 (en) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP4125848A1 (en) 2020-03-26 2023-02-08 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of covid-19
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
US20240115527A1 (en) * 2020-11-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels
EP4678171A1 (en) 2024-07-10 2026-01-14 Dompé farmaceutici SpA Systemically-administered cxcl8 inhibitors for use in the prevention or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4686469A1 (en) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities
EP4686472A1 (en) 2024-08-02 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of ocular graft-versus-host disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082707A (en) * 1973-01-08 1978-04-04 Societa Italo-Britannica L. Manetti-H. Roberts & Co. 2-(4-isobutylphenyl)-propiohydroxamic acid and a procedure for its preparation
JPS53111030A (en) * 1977-02-08 1978-09-28 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivatives
US4786316A (en) * 1984-07-13 1988-11-22 E. I. Du Pont De Nemours And Company Herbicidal ortho-sulfamoyl sulfonamides
US5006542A (en) * 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
EP0579739A4 (en) * 1991-04-10 1994-03-22 Univ Boston INTERLEUKIN 8 RECEPTORS, MOLECULES AND RELATED METHODS.
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
KR19990036127A (ko) * 1995-08-03 1999-05-25 로즈 암스트롱 지방단백질의 농도를 감소시키는 의약의 제조를 위한 술팜산 유도체, 아실 술폰아미드 또는 술포닐 카르바메이트의 용도
KR100284382B1 (ko) * 1995-08-22 2001-03-02 미즈노 마사루 아미드화합물 및 그의 용도
EP1019035A4 (en) * 1996-08-21 2001-10-17 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
PT964849E (pt) * 1997-01-29 2003-08-29 Pfizer Derivados de sulfonilureia e sua utilizacao no controlo da actovidade da interleucina-1

Also Published As

Publication number Publication date
CA2347752C (en) 2009-12-22
JP2002528434A (ja) 2002-09-03
CA2347752A1 (en) 2000-05-04
US6881755B2 (en) 2005-04-19
NO20012000D0 (no) 2001-04-23
SK286372B6 (sk) 2008-08-05
IL142496A0 (en) 2002-03-10
AU769850B2 (en) 2004-02-05
ATE230723T1 (de) 2003-01-15
WO2000024710A1 (en) 2000-05-04
HUP0103793A2 (hu) 2002-03-28
CN1615833A (zh) 2005-05-18
US20030216392A1 (en) 2003-11-20
PL347947A1 (en) 2002-04-22
HU225107B1 (en) 2006-06-28
KR100484370B1 (ko) 2005-04-22
BRPI9914741A (pt) 2001-07-03
ITMI982280A0 (it) 1998-10-23
RU2255084C2 (ru) 2005-06-27
EE200100233A (et) 2002-08-15
NZ525084A (en) 2004-08-27
CZ20011441A3 (cs) 2001-10-17
US6887903B1 (en) 2005-05-03
NZ511077A (en) 2003-08-29
DK1123276T3 (da) 2003-04-28
NO20012000L (no) 2001-06-20
CZ296434B6 (cs) 2006-03-15
PT1123276E (pt) 2003-04-30
PL212210B1 (pl) 2012-08-31
DE69904852D1 (de) 2003-02-13
BRPI9914741B1 (pt) 2012-11-27
KR20010086435A (ko) 2001-09-12
DE69904852T2 (de) 2003-11-13
BRPI9914741B8 (pt) 2021-07-06
SK5382001A3 (en) 2001-12-03
EP1123276B1 (en) 2003-01-08
JP4194761B2 (ja) 2008-12-10
EE04912B1 (et) 2007-10-15
ITMI982280A1 (it) 2000-04-23
CN1324344A (zh) 2001-11-28
HK1041255B (zh) 2008-07-18
TR200101124T2 (tr) 2001-10-22
NO327537B1 (no) 2009-08-03
AU1037500A (en) 2000-05-15
CN100368394C (zh) 2008-02-13
ES2190264T3 (es) 2003-07-16
EP1123276A1 (en) 2001-08-16
HUP0103793A3 (en) 2003-09-29
HK1041255A1 (zh) 2002-07-05

Similar Documents

Publication Publication Date Title
IT1303249B1 (it) Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
RU94022258A (ru) Новые сульфониламинопиримидины
ATE270817T1 (de) Fungizide
TR200103493T2 (tr) Metaloproteaz önleyicileri
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
TR199802344A2 (xx) �kame edilmi� imidazolidin t�revleri
DE69933897D1 (de) Carbamat und Carbazat Ketolid Antibiotika
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
ATE165101T1 (de) Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
ATE269313T1 (de) Tryptase-inhibitoren
PT1244614E (pt) Inibidores de triptase
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
RU95106652A (ru) Оптически активные производные карбоксамида, аналгезирующее средство
DE60003074D1 (de) Fusidinsäure-derivate
RU95113586A (ru) Производные n-/2-амино-2-оксоэтил/бугандиамида или их кислотноаддитивные соли и фармацевтическая композиция со свойствами ингибитора ренина
SE9902596D0 (sv) Pharmaceutically active compounds
MX9804797A (es) Nuevos compuestos con efecto analgesico.
MX9804798A (es) Nuevos compuestos con efecto analgesico.

Legal Events

Date Code Title Description
0001 Granted